Home pageATBPF • OTCMKTS
add
Antibe Therapeutics Ord Shs
Chiusura precedente
0,22 $
Intervallo annuale
0,11 $ - 0,89 $
Volume medio
27.544,00
Rapporto P/E
-
Dividendo/Prezzo
-
Notizie del mercato finanziario
Investor's Business Daily
58 minuti fa
Dow Jones Retail Giant Walmart, Meta Stock In Or Near Buy Zones
1,61%
Dati finanziari
Conto economico
Entrate
Utile netto
| (CAD) | dic 2023info | Variazione Y/Y |
|---|---|---|
Entrate | — | — |
Spese di gestione | 4,60 Mln | -1,42% |
Utile netto | -4,21 Mln | 2,39% |
Margine di profitto netto | — | — |
Utili per azione | -0,08 | 0,50% |
EBITDA | — | — |
Aliquota fiscale effettiva | — | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (CAD) | dic 2023info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 24,91 Mln | -41,20% |
Totale attivo | 56,36 Mln | -23,56% |
Totale passivo | 30,42 Mln | -0,13% |
Patrimonio netto totale | 25,94 Mln | — |
Azioni in circolazione | 52,67 Mln | — |
Prezzo/valore contabile | 0,44 | — |
Redditività dell'attivo | -19,71% | — |
Rendimento sul capitale | -41,30% | — |
Flusso di cassa
Flusso di cassa netto
| (CAD) | dic 2023info | Variazione Y/Y |
|---|---|---|
Utile netto | -4,21 Mln | 2,39% |
Liquidità di esercizio | -3,84 Mln | -6,66% |
Contanti da investimenti | 11,04 Mln | 1.975,38% |
Contanti da finanziamenti | — | — |
Flusso di cassa netto | 7,20 Mln | 334,09% |
Flusso di cassa libero | -2,47 Mln | -2.419,13% |
Informazioni
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
Fondazione
2009
Sito web
Dipendenti
11
